Cargando…

Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design

Detalles Bibliográficos
Autor principal:	Zhaori, Getu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262870/ https://www.ncbi.nlm.nih.gov/pubmed/37324599 http://dx.doi.org/10.1002/ped4.12377

Ejemplares similares

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
por: Jones, Jefferson M., et al.
Publicado: (2023)

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
por: Shoukat, Affan, et al.
Publicado: (2023)

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
por: Brady, Tyler, et al.
Publicado: (2023)

Chylothorax in infants and children in China, a very good start
por: Zhaori, Getu
Publicado: (2018)

Respiratory Syncytial Virus Infection in High-Risk Infants
por: Resch, Bernhard
Publicado: (2011)

Smoke evacuation, is it important for prevention of COVID‐19?
por: Zhaori, Getu
Publicado: (2020)

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
por: Simões, Eric A F, et al.
Publicado: (2023)

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis
por: Turalde-Mapili, Maria Wilma R., et al.
Publicado: (2023)

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection
por: Hammitt, Laura, et al.
Publicado: (2021)

The Changing Landscape of Respiratory Syncytial Virus Infections
por: Bem, Reinout A., et al.
Publicado: (2023)

Further standardization and safety issues for antiviral therapy during pregnancy
por: Zhaori, Getu
Publicado: (2020)

Old problem may have new solution
por: Zhaori, Getu
Publicado: (2018)

Pediatric Investigation, what differences can it make?
por: Zhaori, Getu
Publicado: (2017)

A new column in this journal – Forum on Clinical Investigation
por: Zhaori, Getu
Publicado: (2023)

Is IL-1β a Target for Reducing Hospitalization of Infants Infected with Respiratory Syncytial Virus?
por: Mebratu, Yohannes A., et al.
Publicado: (2021)

The prevention of respiratory syncytial virus infection
por: Bollani, L, et al.
Publicado: (2014)

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
por: Ahani, Bahar, et al.
Publicado: (2023)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

An update on respiratory syncytial virus
por: Piralla, Antonio, et al.
Publicado: (2023)

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
por: Simões, Eric A F, et al.
Publicado: (2020)

Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
por: Resch, Bernhard, et al.
Publicado: (2011)

Respiratory syncytial virus infection in infants in rural Nepal
por: Chu, Helen Y., et al.
Publicado: (2016)

Congenital chylothorax: Rare disease, wide concern
por: Shen, Kunling, et al.
Publicado: (2017)

Respiratory Syncytial Virus Resurgence in Italy: The Need to Protect All Neonates and Young Infants
por: Bozzola, Elena
Publicado: (2021)

Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV) Update
por: Krilov, Leonard R., et al.
Publicado: (2022)

89. The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study
por: Faust, Saul N, et al.
Publicado: (2023)

Respiratory Syncytial Virus Infections in Infants Affected by Primary Immunodeficiency
por: Lanari, Marcello, et al.
Publicado: (2014)

Transient Neutropenia in Immunocompetent Infants with Respiratory Syncytial Virus Infection
por: Korematsu, Tatsuya, et al.
Publicado: (2021)

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
por: Wilkins, Deidre, et al.
Publicado: (2023)

Respiratory syncytial virus infection in COVID-19 times: Trick or threat?
por: Menasalvas Ruiz, Ana Isabel
Publicado: (2023)

Respiratory syncytial virus infection in COVID-19 times: Trick or threat?
por: Menasalvas Ruiz, Ana Isabel
Publicado: (2023)

Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections
por: Jun, Shelly, et al.
Publicado: (2019)

The Respiratory Mucosa: Front and Center in Respiratory Syncytial Virus Disease
por: Thwaites, Ryan S., et al.
Publicado: (2019)

Pranlukast treatment and the use of respiratory support in infants with respiratory syncytial virus infection
por: Kubota, Jun, et al.
Publicado: (2022)

Replication and Clearance of Respiratory Syncytial Virus : Apoptosis Is an Important Pathway of Virus Clearance after Experimental Infection with Bovine Respiratory Syncytial Virus
por: Viuff, Birgitte, et al.
Publicado: (2002)

Better design leads to better results – Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019
por: Zhaori, Getu, et al.
Publicado: (2023)

Antibiotic Minocycline Prevents Respiratory Syncytial Virus Infection
por: Bawage, Swapnil S., et al.
Publicado: (2019)

The disease burden of respiratory syncytial virus in Infants
por: Munro, Alasdair P.S., et al.
Publicado: (2023)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_il1nnjcqcnso5vanailagr2f02